Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Target Price at $77.67

Corcept Therapeutics Incorporated (NASDAQ:CORT) has been given an average recommendation of “Moderate Buy” by the eight research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $77.6667.

Several equities analysts have recently commented on the company. Zacks Research downgraded Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. UBS Group began coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price for the company. Wolfe Research raised Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research note on Thursday, March 26th. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Finally, Truist Financial upgraded Corcept Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Lifyorli FDA approval and analyst upgrade — Seeking Alpha reports an early FDA approval for Lifyorli in platinum‑resistant ovarian cancer, citing a 35% reduction in risk of death, good tolerability, and analyst upgrades that model 2026 sales of $900M–$1B. That outcome materially improves Corcept’s growth narrative and could offset declines in legacy product sales. Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade)
• Negative Sentiment: Widespread securities‑class‑action activity — Numerous law firms (Hagens Berman, Rosen, Pomerantz, Bragar Eagel & Squire, Glancy, Schall, Portnoy, DJS and others) have issued investor alerts and motions seeking lead plaintiff status in a suit alleging Corcept concealed FDA warnings and other adverse information during the cited class period; the lead‑plaintiff deadline is April 21, 2026. This cluster of filings raises potential financial exposure, management distraction, and short‑term downside risk. CORT INVESTOR UPDATE: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT opened at $40.31 on Friday. The stock has a market cap of $4.29 billion, a PE ratio of 49.16 and a beta of 0.29. Corcept Therapeutics has a 1 year low of $28.66 and a 1 year high of $117.33. The firm has a fifty day moving average price of $37.69 and a 200-day moving average price of $60.12. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. During the same quarter last year, the firm posted $0.26 EPS. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. Equities analysts anticipate that Corcept Therapeutics will post 1.36 earnings per share for the current fiscal year.

Insider Transactions at Corcept Therapeutics

In related news, Director G Leonard Baker, Jr. bought 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was purchased at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the completion of the transaction, the director owned 1,146,631 shares in the company, valued at $37,999,351.34. The trade was a 9.55% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider William Guyer sold 20,000 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total transaction of $817,400.00. Following the transaction, the insider directly owned 1,235 shares of the company’s stock, valued at $50,474.45. The trade was a 94.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 86,198 shares of company stock valued at $3,552,769. 20.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at approximately $25,000. Clearstead Advisors LLC increased its position in shares of Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 193 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in Corcept Therapeutics by 598.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 395 shares during the period. Larson Financial Group LLC raised its holdings in Corcept Therapeutics by 2,326.3% during the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 442 shares during the period. Finally, Gould Capital LLC lifted its position in Corcept Therapeutics by 50.0% in the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after buying an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.